American Society of Hematology Annual Meeting

Which posters were hot at ASH 2011?

By Pieter Droppert on December 16, 2011

In my final post about the 2011 American Society of Hematology (ASH) annual meeting, I want to highlight a few of the 4000+ posters that appeared to attract a lot of interest.

The three ASH poster sessions in the equivalent of an aircraft hangar, had a lot of interesting science and clinical data.

All the posters had merit in order to be selected for publication, so my selection is entirely subjective:

Bruton’s Tyrosine Kinase (BTK)

Two posters on products targeting BTK attracted a lot of traffic:

#3485 Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the treatment of B Cell malignancies

This is a preview of Which posters were hot at ASH 2011?. Read the full post

AML update from 2011 ASH annual meeting

By Pieter Droppert on December 15, 2011

At the recent American Society of Hematology (ASH) annual meeting in San Diego, I had the opportunity to hear a few presentations on Acute Myeloid Leukemia (AML).

Those of you familiar with the ASH annual meeting will know that most of the oral presentations for the biology and therapies take place in simultaneous sessions on Monday. This sadly results in many session conflicts if you want to follow several products, pathways or multiple disease areas.

It’s unfortunate that there’s no virtual meeting such as at ASCO or that presentations are not more spread out during the meeting. My AML update is therefore focused specifically on FLT3 inhibition.

This is a preview of AML update from 2011 ASH annual meeting. Read the full post

CML update from 2011 ASH annual meeting

By Pieter Droppert on December 14, 2011

The annual meeting of the American Society of Hematology (ASH) took place in San Diego this past weekend. There was a lot of interesting science, and over the next three posts I will be writing a brief summary of what caught my attention in CML, AML and the poster sessions.

Brian Druker Janet Rowley ASH 2011 Award CML update from 2011 ASH annual meeting

Brian J. Druker & Janet D. Rowley received the Ernest Beutler prize and presented a lecture on “Chronic Myeloid Leukemia (CML): A Success Story from Chromosomes to Effective Therapy.”

As a result of the development of imatinib (originally STI571), “CML has been converted to a manageable condition”, said Druker.

This is a preview of CML update from 2011 ASH annual meeting. Read the full post

Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘American Society of Hematology Annual Meeting’

Which posters were hot at ASH 2011?

AML update from 2011 ASH annual meeting

CML update from 2011 ASH annual meeting